1. Pink Sheet
  2. >>Vaccines

COVID Vaccine Distribution Plan From National Academies Leaves Room For Adjustments Based On Trial Results

 
• By Sarah Karlin-Smith

Draft allocation framework expects health care workers would take up much of the initial vaccine supply and suggests the elderly and people with two comorbid conditions receive vaccination next. NAM suggests states get a population-based allotment, leaving local officials to make many of the tough decisions under the framework, which could be adjusted based on clinical trial data. 

Covid19_Vaccine_Vial
The National Academies of Medicine draft report will be used to guide CDC and state allotment strategies • Source: Shutterstock

The US National Academy of Medicines recommends a four-phased approach to an equitable COVID-19 vaccination campaign starting with “frontline” health care workers, older adults living in congregate settings and individuals with certain high-risk comorbid conditions, but says that “mid-course corrections” to the plan will be the rule as adjustments will need to be made as evidence from vaccine trials, including the degree of efficacy and safety become available. 

Specific data on how vaccines work in older adults and individuals previously infected with COVID-19 are two key factors that could require recommendations to be adjusted

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Vaccines

More from Pink Sheet

EU Shaping Biotech Act To Unleash SME Potential

 
• By Neena Brizmohun

European companies, in particular small and midsize enterprises, spin-offs and start-ups have a hard time expanding within the single market “because of a complex regulatory framework that is perceived as slow and burdensome,” according to the European Commission.

New EU Filings

 
• By Neena Brizmohun

Brensocatib, Insmed's investigational treatment for non-cystic fibrosis bronchiectasis, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

‘Tectonic’ Arkansas PBM Legislation May Upend Industry

 
• By Tim Casey

Industry will fight hard to prevent other states or the federal government from adopting measures similar to Arkansas' law preventing PBMs from owning pharmacies.